Skip to main content
. Author manuscript; available in PMC: 2015 Jan 14.
Published in final edited form as: Semin Liver Dis. 2014 Nov 4;34(4):456–464. doi: 10.1055/s-0034-1394144

Fig. 1.

Fig. 1

Molecular pathways in cholangiocarcinoma (CCA) and inhibitors. Several molecular pathways are dysregulated in CCA. Inhibitors targeting these pathways are entering human clinical trials. The prevalence of each genetic aberration and potential therapeutic strategies are listed.